AMSBIO has expanded its range of primary human cancer cells sourced from a wide variety of tissue types that allow the study of cancer in a more in vivo like fashion.

Many scientists acknowledge that using immortalized cell lines as surrogates offers only a poor reflection of the diverse profiles of real cancer tumors. During long-term culture, immortalized cells adapt to their in vitro environment, and often mask or lose the in vivo phenotypic events being studied – in addition to hiding key epigenetic or immunotherapy markers. These shortfalls highlight the need for new in vitro cancer models, utilizing primary tumor cells that more closely reproduce the in vivo cancer microenvironment.

Traditionally, cancer drug discovery has relied on the same limited selection of models that have been in use for decades. Progress in recent years has however highlighted the tremendous heterogeneity of the disease, leading which has led to a more urgent focus on precision medicine; as well as advanced treatments such as immunotherapy and the use of oncolytic viruses. Donor-derived primary tumor cells from AMSBIO offer a more in vivo like model - potentially enhancing the development of targeted personalized therapeutics.

AMSBIO’s range of primary human cancer cells are available for specific tumor types, both primary and metastasis. All exhibit heterogenous cell populations with diverse genetic backgrounds. Provided with the original pathological diagnoses and analyzed for key mutations, these primary human cancer cells present the real characteristics of their in vivo state, remain heterogeneous for several passages and thus enhance pharmacogenetic and molecular diagnostic testing abilities. Typical applications that will benefit from these products include drug discovery and development, drug testing, drug screening, basic research as well as functional and cytotoxicity analyses.

This expanded range of patient-specific cells, which includes breast and prostate primary cancer cells available from multiple donors, adds to the range of products offered by AMSBIO to help researchers develop more physiologically relevant models to study cell behavior.

For further information on patient-derived primary human cancer cells please visit https://www.amsbio.com/human-primary-cancer-cells/ or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / [email protected].

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.

 
---------------------

Worldwide HQ

AMS Biotechnology (AMSBIO)
184 Milton Park
Abingdon
Oxon OX14 4SE
UK

Tel: +44-1235-828200
Fax: +44-1235-820482
Email: [email protected]
Web www.amsbio.com